First-in-human study of first-in-class fatty acid synthase inhibitor, TVB-2640

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a first-in-human study of the first-in-class fatty acid synthase inhibitor, TVB-2640, as monotherapy or in combination for the treatment of patients with solid malignancies.

Year of Production:
Running Time:
Color/Sound:

2015
03:31
Color/Sound

Comments are closed.